Literature DB >> 21576637

Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.

Hans Carl Hasselbalch, Jean-Jacques Kiladjian, Richard T Silver.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21576637     DOI: 10.1200/JCO.2011.35.6238

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Authors:  R Tamari; T I Mughal; D Rondelli; R Hasserjian; V Gupta; O Odenike; V Fauble; G Finazzi; F Pane; J Mascarenhas; J Prchal; S Giralt; R Hoffman
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 2.  Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.

Authors:  J Mascarenhas; T I Mughal; S Verstovsek
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 3.  Guidelines for the management of myeloproliferative neoplasms.

Authors:  Chul Won Choi; Soo-Mee Bang; Seongsoo Jang; Chul Won Jung; Hee-Jin Kim; Ho Young Kim; Soo-Jeong Kim; Yeo-Kyeoung Kim; Jinny Park; Jong-Ho Won
Journal:  Korean J Intern Med       Date:  2015-10-30       Impact factor: 2.884

Review 4.  MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.

Authors:  Hans Carl Hasselbalch; Mads Emil Bjørn
Journal:  Mediators Inflamm       Date:  2015-10-28       Impact factor: 4.711

Review 5.  Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses.

Authors:  Vibe Skov
Journal:  Cancers (Basel)       Date:  2020-08-06       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.